# PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT

> **NCT04669210** · PHASE2 · COMPLETED · sponsor: **St. Petersburg State Pavlov Medical University** · enrollment: 128 (actual)

## Conditions studied

- Graft-versus-host-disease
- Stem Cell Transplant Complications
- Acute Myeloid Leukemia
- Acute Lymphoid Leukemia

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate Mofetil

## Key facts

- **NCT ID:** NCT04669210
- **Lead sponsor:** St. Petersburg State Pavlov Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-03
- **Primary completion:** 2023-02-27
- **Final completion:** 2025-03-28
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04669210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04669210, "PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04669210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*